Tags

Type your tag names separated by a space and hit enter

[Treatment of malignancy-associated hypercalcemia].
Clin Calcium. 2006 Apr; 16(4):665-69.CC

Abstract

Malignancy-associated hypercalcemia (MAH) is caused by tumor over-production of parathyroid hormone-related protein (PTHrP), or by locally enhanced bone resorption in metastatic lesions of solid cancers. Medical treatment of MAH includes hydration by saline infusion, loop diuretics to promote urinary calcium excretion and anti-resorptives such as calcitonin and bisphosphonates. Particularly, bisphosphonates are the current mainstay for MAH treatment : they not only inhibit osteoclastic bone resorption to ameliorate hypercalcemia but can also alleviate bone pain and can even prevent cancer cell expansion in bone metastatic lesions.

Authors+Show Affiliations

Endo I
University of Tokushima, Graduate School Institute of Health Biosciences, Department of Medicine and Bioregulatory Sciences.
Inoue D
No affiliation info available

MeSH

Bone NeoplasmsBone ResorptionCalcitoninDiphosphonatesDrug DesignDrug Therapy, CombinationFluid TherapyGlycoproteinsHumansHypercalcemiaNeoplasmsOsteoprotegerinParathyroid Hormone-Related ProteinReceptors, Cytoplasmic and NuclearReceptors, Tumor Necrosis FactorSodium ChlorideSodium Potassium Chloride Symporter Inhibitors

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

16582519

Citation

Endo, Itsuro, and Daisuke Inoue. "[Treatment of Malignancy-associated Hypercalcemia]." Clinical Calcium, vol. 16, no. 4, 2006, pp. 665-69.
Endo I, Inoue D. [Treatment of malignancy-associated hypercalcemia]. Clin Calcium. 2006;16(4):665-69.
Endo, I., & Inoue, D. (2006). [Treatment of malignancy-associated hypercalcemia]. Clinical Calcium, 16(4), 665-69.
Endo I, Inoue D. [Treatment of Malignancy-associated Hypercalcemia]. Clin Calcium. 2006;16(4):665-69. PubMed PMID: 16582519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of malignancy-associated hypercalcemia]. AU - Endo,Itsuro, AU - Inoue,Daisuke, PY - 2006/4/4/pubmed PY - 2006/6/28/medline PY - 2006/4/4/entrez SP - 665 EP - 69 JF - Clinical calcium JO - Clin Calcium VL - 16 IS - 4 N2 - Malignancy-associated hypercalcemia (MAH) is caused by tumor over-production of parathyroid hormone-related protein (PTHrP), or by locally enhanced bone resorption in metastatic lesions of solid cancers. Medical treatment of MAH includes hydration by saline infusion, loop diuretics to promote urinary calcium excretion and anti-resorptives such as calcitonin and bisphosphonates. Particularly, bisphosphonates are the current mainstay for MAH treatment : they not only inhibit osteoclastic bone resorption to ameliorate hypercalcemia but can also alleviate bone pain and can even prevent cancer cell expansion in bone metastatic lesions. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/16582519/[Treatment_of_malignancy_associated_hypercalcemia]_ DB - PRIME DP - Unbound Medicine ER -